USPTO serial 79266012
LETYBO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 27, 2020
- Examiner
- MCMORROW, JANICE LEE
- Law office
- TMO LAW OFFICE 115
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with LETYBO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*
Plus Government fees of $425
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
James R Menker
James R Menker Holley & Menker, PA60 Ocean Boulevard, Suite 3Atlantic Beach, FL 32233United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of spasm; pharmaceutical preparations for treating dystonia; muscle relaxants; pharmaceutical products for skin care for animals; pharmaceutical preparations used in cosmetic surgery; pharmaceutical preparations containing botulinum toxin; botulinum toxin for medical use for use in the treatment of neuropathy pain; pharmaceutical preparations containing botulinum toxin for the treatment of wrinkles; pharmaceutical preparations containing botulinum toxin fragments for the treatment of wrinkles; pharmaceutical preparations for use in treating urogenital system diseases and conditions, namely, overactive bladder and urinary incontinence; bacterial toxins, namely, bacterial poisons; pharmaceutical preparations for digestive system; pharmacological preparations for skin care; pharmaceutical preparations for treating peripheral neurological diseases and disorders; pharmaceutical preparations for treating central neurological diseases and disorders; ophthalmic preparations for use in the treatment of blepharospasm and strabismus; medicated ointments for treating dermatological conditions; chemical preparations for [ phamaceutical ] * pharmaceutical * purposes for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, wrinkles, hyperhydrosis and cerebral palsy; chemical preparations for [ phamaceutical ] * pharmaceutical * purposes for the treatment of sports injuries, namely, injured or torn skin, muscle, ligaments or bone; chemical preparations for [ phamaceutical ] * pharmaceutical * purposes for the treatment of tremors, namely, spasmodic smooth, striated or cardiac muscles; chemical preparations for [ phamaceutical ] * pharmaceutical * purposes for the treatment of pain, namely, smooth muscle pain, striated muscle pain, cardiac muscle pain, neuropathic pain, inflammatory pain, visceral pain, chronic pain, acute pain, traumatic injury pain, referred pain, growing pain, hunger pain, intractable pain, labour pain, organic pain, phantom limb pain, postprandial pain, psychogenic pain, back pain, post-stroke pain, cancer pain, nociceptive pain, headache pain, prostatic pain, and bladder pain; pharmaceutical agents for epidermis; drugs for medical purposes for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, wrinkles, hyperhydrosis and cerebral palsy; drugs for medical purposes for the treatment of sports injuries, namely, injured or torn skin, muscle, ligaments or bone; drugs for medical purposes for the treatment of tremors, namely, spasmodic smooth, striated or cardiac muscles; drugs for medical purposes for the treatment of pain, namely, smooth muscle pain, striated muscle pain, cardiac muscle pain, neuropathic pain, inflammatory pain, visceral pain, chronic pain, acute pain, traumatic injury pain, referred pain, growing pain, hunger pain, intractable pain, labour pain, organic pain, phantom limb pain, postprandial pain, psychogenic pain, back pain, post-stroke pain, cancer pain, nociceptive pain, headache pain, prostatic pain, and bladder pain; biological preparations for medical or veterinary purposes for the treatment of aesthetic dermatology, orthopaedics, arthritis and ophthalmology; cultures of microorganisms for medical or veterinary use; chemical reagents for medical or veterinary purposes; bacteriological preparations for medical and veterinary use; adjuvants for medical purposes; hyaluronic acid preparations for medical purposes; medicines for human purpose, namely, medicines for skin care; pharmaceutical preparations for the treatment of psychiatric diseases and disorders; pharmaceutical preparations for the treatment of orthopaedic disorders, namely, hip dislocation, spinal column deformation, curvature of the spine, namely, scoliosis, lordosis, cyphosis; pharmaceutical preparations for smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, tremors and pain; pharmaceutical preparations for the treatment of wrinkles; injectable dermal filler; medicines for dental purposes; preparation for the relief of pain; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations mainly based on hyaluronic acid for treatments, namely, injectable for intradermal and subcutaneous application for facial and body skin tightening and smoothing; botulinum toxin for medical use for use in the treatment of excessive sweating, excessive eye blinking, neuropathy pain, facial wrinkles, headache, pain, spasm, dystonia, urogenital system diseases and conditions, skin disorders; therapeutic drugs and agents for use in the treatment of excessive sweating, excessive eye blinking, neuropathy pain, facial wrinkles, headache, pain, spasm, dystonia, urogenital system diseases and conditions, skin disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 27, 2026 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Oct 27, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Aug 29, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Aug 13, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 13, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Feb 21, 2025 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Feb 5, 2025 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Dec 12, 2024 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| May 21, 2024 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| Apr 12, 2024 | CORR | CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED | — |
| Apr 11, 2024 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Mar 17, 2024 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Mar 7, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 27, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 6, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 6, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 27, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 27, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 11, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 11, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 7, 2020 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jul 22, 2020 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 22, 2020 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jul 22, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 6, 2020 | ISMR | WITHDRAWN FROM ISSUE - MANAGING ATTORNEY REQUEST | — |
| May 12, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 12, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 22, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 26, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 12, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 12, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 12, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 12, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 5, 2019 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 16, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 16, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 10, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 6, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 5, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 4, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 4, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 26, 2019 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Aug 22, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |